Abstract:Ulrich, Silvia, Mona Lichtblau, Simon R. Schneider, Stéphanie Saxer, and Konrad E. Bloch, Clinician's corner: counseling patients with pulmonary vascular disease traveling to high altitude. High Alt Med Biol. 23:201-208, 2022.-Pulmonary vascular diseases (PVDs) with precapillary pulmonary hypertension (PH), such as pulmonary arterial or chronic thromboembolic PH, impair exercise performance and survival in patients. Vasodilators and other treatments improve quality of life and prognosis to an extent in patients who have PVDs as chronic disorders. Obviously, patients with PVD wish to participate in usual daily activities, including travel to popular settlements and mountainous regions located at high altitude. However, the pulmonary hemodynamic impairment due to PVD leads to blood and tissue hypoxia, particularly during exercise and sleep. It is thus of concern that alveolar hypoxia at higher altitude may exacerbate patients' symptoms and lead to decompensation. Current PH guidelines discourage high-altitude exposure for fear of altitude-related adverse health effects. However, several recent well-designed prospective and randomized trials show that despite altitude-induced hypoxemia, pulmonary hemodynamic changes and impairment of exercise performance in patients with PVD are similar to the responses in healthy people or in patients with mild chronic obstructive pulmonary disease. The vast majority of patients with PVD can tolerate short-term exposure to moderate altitudes up to 2,500 m. For the roughly 10% of patients with stable disease who develop severe hypoxemia when ascending to 2,500 m, they respond well to low-level supplemental oxygen support. The best low-altitude predictors for adverse health effects at high altitude are the known clinical risk factors for PVD such as symptoms, functional class, exercise capacity, and exertional oxygen desaturation, whereas hypoxia altitude simulation testing is of little additive value. In any case, patients should be instructed that altitude-related adverse health effects may be difficult to predict and that in case of worsening symptoms, immediate accompanied descent to lower altitude and oxygen therapy are required. Patients with severe hypoxemia near sea level may safely visit high-altitude regions up to 1,500-2,000 m while continuing oxygen therapy and avoiding strenuous exercise. All PH patients should be counseled before any high-altitude sojourn by doctors with experience in PVD and high-altitude medicine and have an action plan for the occurrence of severe hypoxemia and other altitude-related conditions such as acute mountain sickness.

High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine

Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence

Fenfluramine-induced Gene Dysregulation in Human Pulmonary Artery Smooth Muscle and Endothelial Cells.

Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders

Anti-hypotensive treatment and endothelin blockade synergistically antagonize exercise fatigue in rats under simulated high altitude

Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine

Research advances in pathogenesis and prophylactic measures of acute high altitude illness

Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension

The combination of theophylline and endothelin receptor antagonism improves exercise performance of rats under simulated high altitude

[Acute mountain sickness and high altitude cerebral and pulmonary edema]

Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated

Pulmonary vascular diseases at high altitude - is it safe to live in the mountains?

New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments

Altitude illnesses

Clinician's Corner: Counseling Patients with Pulmonary Vascular Disease Traveling to High Altitude

Risk factors underlying high-altitude pulmonary edema in the Ecuadorian Andes

High-altitude medicine

Effect of furosemide in the treatment of high-altitude pulmonary edema

Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling